Follow the people · Insider
Susan Bobulsky
Susan Bobulsky files insider transactions with the SEC as a chief commercial officer, mrd of Adaptive Biotechnologies (ADPT). We hold 8 disclosed purchases and sales filed since 14 August 2020, 6 of them in the last 90 days.
- Files forADPT
- Disclosed buys and sells8 in all, 6 in the last 90 days
- Last disclosure12 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 August 2020 — 10 August 2026Chief Commercial Officer, MRD · Adaptive Biotechnologies (ADPT)31 Form 4 lines · source: SEC Form 4
Everything they disclosed
31 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,000 shares of Adaptive BiotechnologiesSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 1,299 shares of Adaptive BiotechnologiesSEC Form 43 August 2026Common Stock · traded 30 July 2026 · filed 3 August 2026
- ▼ sold on the open market 5,000 shares of Adaptive BiotechnologiesSEC Form 420 July 2026Common Stock · traded 16 July 2026 · filed 20 July 2026
- ▼ sold on the open market 487 shares of Adaptive BiotechnologiesSEC Form 46 July 2026Common Stock · traded 1 July 2026 · filed 6 July 2026
- ▼ sold on the open market 5,000 shares of Adaptive BiotechnologiesSEC Form 429 June 2026Common Stock · traded 25 June 2026 · filed 29 June 2026
- ▼ sold on the open market 5,000 shares of Adaptive BiotechnologiesSEC Form 415 June 2026Common Stock · traded 11 June 2026 · filed 15 June 2026
- ▼ sold on the open market 11,000 shares of Adaptive BiotechnologiesSEC Form 48 June 2026Common Stock · traded 4 June 2026 · filed 8 June 2026
- ▼ sold on the open market 41,338 shares of Adaptive BiotechnologiesSEC Form 413 March 2026Common Stock · traded 11 March 2026 · filed 13 March 2026
- ▼ sold on the open market 41,338 shares of Adaptive BiotechnologiesSEC Form 413 March 2026Common Stock · traded 11 March 2026 · filed 13 March 2026
- was granted 59,375 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- was granted 62,500 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- was granted 59,375 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- was granted 62,500 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- was granted 180,029 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 46 March 2025Stock Option (right to buy) · traded 4 March 2025 · filed 6 March 2025
- was granted 119,971 shares of Adaptive BiotechnologiesSEC Form 46 March 2025Common Stock · traded 4 March 2025 · filed 6 March 2025
- ▼ sold on the open market 26,023 shares of Adaptive BiotechnologiesSEC Form 46 March 2025Common Stock · traded 5 March 2025 · filed 6 March 2025
- exercised options over 5,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 410 October 2024Stock Option (right to buy) · traded 8 October 2024 · filed 10 October 2024
- exercised options over 5,000 shares of Adaptive BiotechnologiesSEC Form 410 October 2024Common Stock · traded 8 October 2024 · filed 10 October 2024
- was granted 199,549 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 46 March 2024Stock Option (right to buy) · traded 4 March 2024 · filed 6 March 2024
- was granted 132,979 shares of Adaptive BiotechnologiesSEC Form 46 March 2024Common Stock · traded 4 March 2024 · filed 6 March 2024
- ▼ sold on the open market 6,016 shares of Adaptive BiotechnologiesSEC Form 46 March 2024Common Stock · traded 5 March 2024 · filed 6 March 2024
- ▼ sold on the open market 6,975 shares of Adaptive BiotechnologiesSEC Form 46 March 2024Common Stock · traded 5 March 2024 · filed 6 March 2024
- was granted 22,894 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 48 March 2021Stock Option (Right to Buy) · traded 4 March 2021 · filed 8 March 2021
- was granted 9,158 shares of Adaptive BiotechnologiesSEC Form 48 March 2021Common Stock · traded 4 March 2021 · filed 8 March 2021
- exercised options over 25,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 411 December 2020Stock Option (Right to Buy) · traded 10 December 2020 · filed 11 December 2020
- exercised options over 25,000 shares of Adaptive BiotechnologiesSEC Form 411 December 2020Common Stock · traded 10 December 2020 · filed 11 December 2020
- ▼ sold on the open market 25,000 shares of Adaptive BiotechnologiesSEC Form 411 December 2020Common Stock · traded 10 December 2020 · filed 11 December 2020
- exercised options over 10,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 41 October 2020Stock Option (Right to Buy) · traded 29 September 2020 · filed 1 October 2020
- exercised options over 10,000 shares of Adaptive BiotechnologiesSEC Form 41 October 2020Common Stock · traded 29 September 2020 · filed 1 October 2020
- ▼ sold on the open market 10,000 shares of Adaptive BiotechnologiesSEC Form 41 October 2020Common Stock · traded 29 September 2020 · filed 1 October 2020
- was granted 20,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 414 August 2020Stock Option (Right to Buy) · traded 13 August 2020 · filed 14 August 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.